Sana Biotechnology, Inc. — Q1 2024 Form 10-Q
Business context and reporting period
Quarter ended March 31, 2024; filed May 8, 2024. Sana is a clinical-stage biotechnology company developing engineered-cell medicines. It has no approved products and has not generated revenue from product sales.
The company reports four ongoing or near-term clinical trials: ARDENT and GLEAM evaluating SC291, VIVID evaluating SC262, and an investigator-sponsored study of UP421. These programs cover seven diseases in B-cell malignancies, autoimmune diseases, and type 1 diabetes. Management expected to share data from each trial in 2024. Following its October 2023 repositioning, Sana prioritized ex vivo cell therapies and reduced near-term investment in its fusogen in vivo platform, including delaying SG299’s IND submission.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 or comparator |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $56.4 million | $67.2 million |
| R&D-related success payment and contingent consideration expense | $38.0 million | $0.1 million |
| General and administrative expense | $16.3 million | $16.8 million |
| Total operating expenses / operating loss | $110.7 million | $84.1 million |
| Interest income, net | $3.0 million | $2.0 million |
| Net loss | $107.5 million | $82.1 million |
| Net loss per share, basic and diluted | $0.49 | $0.43 |
| Cash used in operating activities | $65.6 million | $79.3 million |
| Capital expenditures (property and equipment purchases) | $15.8 million | $2.2 million |
Gross and operating margins are not meaningful because Sana has no revenue. Net loss included $32.6 million of non-cash expense from revaluing success payment liabilities and $5.4 million from revaluing contingent consideration. These fair-value charges materially increased reported expenses.
At March 31, 2024, cash and cash equivalents were $177.1 million and marketable securities were $134.0 million, totaling $311.1 million. Restricted cash was an additional $3.8 million. Current assets were $321.3 million and current liabilities $52.9 million; working capital was approximately $268.4 million. Sana reported no debt outstanding. Operating lease liabilities totaled $106.1 million; contingent consideration was $115.0 million and success payment liabilities were $45.4 million.
Financing activities provided $186.4 million in Q1, principally reflecting the February public offering, which generated approximately $180.0 million net from common shares and pre-funded warrants. Investing activities used $77.2 million, including net purchases of marketable securities and property and equipment. Cash, cash equivalents, and restricted cash increased by $43.5 million during the quarter.
Material changes versus the prior comparable period
- Net loss increased by $25.4 million, despite R&D expense falling by $10.7 million. The main driver was a $37.9 million year-over-year increase in R&D-related fair-value expenses, including a $27.9 million Cobalt success payment charge and a $4.7 million Harvard success payment charge; the prior-year period included gains on both liabilities.
- Lower R&D expense primarily reflected reduced personnel costs after the October 2023 workforce reduction, as well as lower manufacturing, laboratory, and facility costs. Clinical development costs partly offset the decline.
- Cash and marketable securities rose from $205.2 million at December 31, 2023 to $311.1 million at March 31, 2024, chiefly due to the February financing. Common shares outstanding increased from 197.9 million to 221.3 million during the quarter; pre-funded warrants for 12.7 million shares were also issued.
- Operating cash use improved by $13.6 million from Q1 2023, while property and equipment purchases increased by $13.7 million.
Outlook, risks, contingencies, and other notable items
- Management said existing cash, cash equivalents, and marketable securities were expected to fund working capital and capital expenditure needs for at least 12 months from the filing of the financial statements. It also expected 2024 operating cash burn below $200 million following the completed repositioning and workforce reduction.
- Management expected operating losses and expenses to decrease in 2024, excluding potential one-time items, and potentially rise over the longer term if clinical trials succeed and development expands. Additional financing will likely be needed; its availability and terms are uncertain.
- The October 2023 repositioning reduced the workforce by approximately 29% and incurred approximately $5.2 million of cash-based severance and related costs. Sana said the restructuring was complete.
- Potential payments under the Cobalt acquisition include up to $500 million of development milestone contingent consideration and a success payment of up to $500 million; Harvard success payments could total up to $175 million. None had been triggered as of March 31, 2024. Their estimated fair values are sensitive to stock price, market capitalization, milestone probabilities, and timing, and can create significant non-cash earnings volatility.
- Key risks include early-stage clinical and regulatory uncertainty; possible serious safety issues, including gene-editing and CAR T risks; manufacturing scale-up and reliance on CDMOs and suppliers; dependence on licensed intellectual property; competition for capital and personnel; and potential dilution from future equity issuance. The filing notes the FDA’s January 2024 class-wide boxed warning requirement concerning T-cell malignancies for approved CAR T therapies.
- Sana reported no material legal proceedings. Management concluded disclosure controls and procedures were effective at a reasonable assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the four clinical studies deliver the anticipated 2024 data readouts, and what the complete safety and efficacy data show.
- Whether the $311.1 million of cash and marketable securities and management’s stated runway remain consistent with actual spending, trial progress, and the below-$200 million 2024 cash-burn expectation.
- How much of the reported loss reflects recurring operating costs versus fair-value remeasurement of success payment and contingent consideration liabilities.
- The potential dilution from the February offering, outstanding pre-funded warrants, employee equity awards, and any future financing.
- Progress, cost, and timing of the Bothell manufacturing facility and the company’s reliance on CDMOs and other suppliers.